Rituximab with high‐dose methotrexate in primary central nervous system lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|12|1149-1154

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.12, 2015-12, pp. : 1149-1154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients

By  

Oncology, Vol. 60, Iss. 2, 2001-02 ,pp. : 134-140

Karger

Access to resources Recommend Favorite

Prognosis Factors in Japanese Elderly Patients with Primary Central Nervous System Lymphoma Treated with a Nonradiation, Intermediate-Dose Methotrexate-Containing Regimen

By  

Oncology Research and Treatment, Vol. 37, Iss. 7-8, 2014-05 ,pp. : 378-383

Karger

Access to resources Recommend Favorite

Addition of Rituximab to High-Dose Methotrexate-Based Chemotherapy Improves Survival of Adults with Burkitt Lymphoma/Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 2, 2011-12 ,pp. : 115-117

Karger

Access to resources Recommend Favorite

Hepatitis B Virus Reactivation in a Primary Central Nervous System Lymphoma Patient following Intrathecal Rituximab Treatment

By  

Acta Haematologica, Vol. 125, Iss. 3, 2010-12 ,pp. : 121-124

Karger

Access to resources Recommend Favorite

Primary Central Nervous System Lymphoma in the Elderly

By  

Oncology Research and Treatment, Vol. 37, Iss. 7-8, 2014-07 ,pp. : 376-377

Karger

Access to resources Recommend Favorite